ClinicalTrials.Veeva

Find clinical trials for Multiple Myeloma in Austin, TX

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Plasma Cell Cancer
Lymphoma
Hematologic Cancer
Leukemia
Cancer
Smoldering Multiple Myeloma
Non-Hodgkin Lymphoma

Multiple Myeloma trials near Austin, TX, USA:

Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma

lenalidomide, and dexamethasone (DRd) for first-line treatment of multiple myeloma (MM).FDA has approved selinexor plus dexamethaso ...

Enrolling
Plasma Cell Myeloma
Myeloma, Plasma Cell
Drug: Selinexor
Drug: Daratumumab

Phase 2

US Oncology Network
US Oncology Network

Austin, Texas, United States and 9 other locations

(DRd) to that of lenalidomide and dexamethasone (Rd), in terms of progression-free survival in participants with relapsed or refractory multiple...

Active, not recruiting
Multiple Myeloma
Drug: Lenalidomide
Drug: Daratumumab

Phase 3

Janssen
Janssen

Austin, Texas, United States and 145 other locations

doses) of the study medicine (elranatamab) in participants with multiple myeloma that has come back after responding to treatment o ...

Active, not recruiting
Multiple Myeloma
Drug: Elranatamab

Phase 2

Pfizer
Pfizer

Austin, Texas, United States and 41 other locations

The purpose of the ALLO-605-201 study is to assess the safety, efficacy, and cell kinetics of ALLO605 in adults with relapsed or refractory multiple...

Active, not recruiting
Relapsed/Refractory Multiple Myeloma
Drug: Cyclophosphamide
Genetic: ALLO-605

Phase 1, Phase 2

Allogene Therapeutics

Austin, Texas, United States and 2 other locations

A Study Evaluating Treatment of Multiple Myeloma with Carfilzomib in Combination with Pomalidomide and Dexamethasone...

Active, not recruiting
Relapsed or Refractory Multiple Myeloma
Drug: Dexamethasone
Drug: Carfilzomib

Phase 2

Amgen
Amgen

Austin, Texas, United States and 45 other locations

trial is a phase 1b/2, open-label, multicenter study of GC012F, a CD19/BCMA dual CART-cell therapy, in adult subjects with relapsed/refractory Multiple...

Enrolling
Relapsed/ Refractory Multiple Myeloma
Biological: GC012F

Phase 1, Phase 2

Gracell Biotechnologies

Austin, Texas, United States and 3 other locations

Phase 1 study comprised of open-label, dose escalation, multiple cohorts of P-BCMA-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells in ...

Enrolling
Multiple Myeloma
Drug: Rimiducid
Biological: P-BCMA-ALLO1 CAR-T cells

Phase 1

Poseida Therapeutics

Austin, Texas, United States and 13 other locations

subcutaneously (SC) prolongs progression-free survival (PFS) compared with active monitoring in participants with high-risk smoldering multiple...

Active, not recruiting
Smoldering Multiple Myeloma
Drug: Daratumumab SC: daratumumab + rHuPH20

Phase 3

Janssen
Janssen

Austin, Texas, United States and 163 other locations

with or without Nirogacestat in adults with relapsed or refractory multiple myeloma after a lymphodepletion regimen of ALLO-647 in ...

Active, not recruiting
Relapsed/Refractory Multiple Myeloma
Genetic: ALLO-715
Drug: Fludarabine

Phase 1

Allogene Therapeutics

Austin, Texas, United States and 10 other locations

The main aim is to evaluate the effect of Ixazomib in combination with lenalidomide and dexamethasone on Multiple Myeloma disease p...

Active, not recruiting
Multiple Myeloma
Drug: Dexamethasone
Drug: Ixazomib

Phase 4

Takeda
Takeda

Austin, Texas, United States and 32 other locations

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems